Summary & Overview
CPT 52214: Transurethral Bladder and Urethral Tissue Destruction
CPT code 52214 identifies transurethral endoscopic destruction (fulguration or ablation) of abnormal tissue in the bladder trigone, bladder neck, prostatic fossa, urethra, or periurethral glands using electrocautery, cryosurgery, or laser. This procedure is a focused urologic intervention commonly used to treat localized lesions, bleeding sources, or obstructive tissue within the lower urinary tract. Nationally, accurate coding of this procedure affects clinical documentation, procedural quality tracking, and payer adjudication for urology services.
Key payers highlighted in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication offers a concise review of how CPT code 52214 is defined, typical sites of service (ambulatory surgical centers and hospital operating rooms), and the clinical contexts in which it is used.
Readers will find benchmarks and coding guidance relevant to billing and claims processing, summaries of payer coverage patterns where available, and clinical context to support accurate charge capture and recordkeeping. The content summarizes common documentation elements associated with the procedure and notes where input data was not provided.
Billing Code Overview
CPT code 52214 describes endoscopic destruction (fulguration) of abnormal tissue in the lower urinary tract. The procedure is performed using a cystoscope passed through the urethra into the bladder to inspect structures and to destroy tissue on the bladder trigone, bladder neck, prostatic fossa, urethra, and/or periurethral glands using high-frequency electric current (electrocautery), intense cold (cryosurgery), or heat (laser surgery).
Service Type: Endoscopic bladder and urethral tissue destruction (fulguration/ablation)
Typical Site of Service: Ambulatory surgical center or hospital operating room; procedures performed via cystoscopy with transurethral access
Clinical & Coding Specifications
Clinical Context
A typical patient is a 68-year-old male with bothersome lower urinary tract symptoms and recurrent episodes of bladder outlet obstruction secondary to benign prostatic hyperplasia (BPH) and symptomatic bladder neck/trigonal lesions. The urologist evaluates the patient in clinic, reviews prior imaging (ultrasound or CT) and uroflowmetry, and documents failed conservative therapy (alpha-blocker and 5-alpha-reductase inhibitor) and persistent urinary retention or recurrent urinary tract infections. After preoperative assessment and informed consent, the patient is scheduled for a transurethral endoscopic procedure in an outpatient ambulatory surgery center or hospital operating room under general or spinal anesthesia.
During the procedure, the surgeon inserts a cystoscope through the urethra to visualize the bladder, bladder neck, trigone, prostatic fossa, periurethral glands, and urethra. The surgeon performs destruction (fulguration, electrocautery, cryotherapy, or laser ablation) of focal tissue on the bladder trigone, bladder neck, prostatic fossa, urethra, and/or periurethral glands to treat lesions contributing to obstruction, bleeding, or recurrent infections. Typical intraoperative documentation includes indication, cystoscopic findings, method of tissue destruction (electrocautery, laser, or cryo), duration, estimated blood loss, any complications, and postoperative catheter plan. Postoperative workflow includes recovery unit monitoring, voiding trial or catheter management, discharge instructions, and follow-up visit for symptom assessment and possible repeat cystoscopy if symptoms persist.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|